PMID- 30394648
OWN - NLM
STAT- MEDLINE
DCOM- 20200415
LR  - 20210109
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 23
IP  - 1
DP  - 2019 Jan
TI  - Picroside II attenuates hyperhomocysteinemia-induced endothelial injury by 
      reducing inflammation, oxidative stress and cell apoptosis.
PG  - 464-475
LID - 10.1111/jcmm.13949 [doi]
AB  - Picroside II (P-II), one of the main active components of scrophularia extract, 
      which have anti-oxidative, anti-inflammatory effects, but its effect on 
      hyperhomocysteinemia (HHcy) induced endothelial injury remains to be determined. 
      Here, we test whether P-II protects HHcy-induced endothelial dysfunction against 
      oxidative stress, inflammation and cell apoptosis. In vitro study using HUVECs, 
      and in hyperhomocysteinemia mouse models, we found that HHcy decreased 
      endothelial SIRT1 expression and increased LOX-1 expression, subsequently causing 
      reactive oxygen species generation, up-regulation of NADPH oxidase activity and 
      NF-kappaB activation, thereby promoting pro-inflammatory response and cell apoptosis. 
      Blockade of Sirt1 with Ex527 or siRNASIRT1 increased LOX-1 expression, whereas 
      overexpression of SIRT1 decreased LOX-1 expression markedly. P-II treatment 
      significantly increased SIRT1 expression and reduced LOX-1 expression, and 
      protected against endothelial cells from Hcy-induced oxidative injury, 
      inflammation and apoptosis. However, blockade of SIRT1 or overexpression of LOX-1 
      attenuated the therapeutic effects of P-II. In conclusion, our results suggest 
      that P-II prevents the Hcy induced endothelial damage probably through regulating 
      the SIRT1/LOX-1 signaling pathway.
CI  - (c) 2018 The Authors. Journal of Cellular and Molecular Medicine published by John 
      Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
FAU - Wang, Yunkai
AU  - Wang Y
AUID- ORCID: 0000-0002-2979-1569
AD  - Department of Cardiology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Hong, Yajun
AU  - Hong Y
AD  - Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, 
      China.
FAU - Zhang, Chunyu
AU  - Zhang C
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Shen, Yunli
AU  - Shen Y
AD  - Department of Cardiology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Pan, Ye Shen
AU  - Pan YS
AD  - Department of Cardiology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Chen, Rui Zhen
AU  - Chen RZ
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Department of Cardiology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Chen, Yi Han
AU  - Chen YH
AD  - Department of Cardiology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181105
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (Antioxidants)
RN  - 0 (Cinnamates)
RN  - 0 (Iridoid Glucosides)
RN  - 0 (NF-kappa B)
RN  - 0 (Reactive Oxygen Species)
RN  - 39012-20-9 (picroside II)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Apoptosis/*drug effects
MH  - Cell Line
MH  - Cinnamates/*pharmacology
MH  - Endothelium/*drug effects/metabolism
MH  - Human Umbilical Vein Endothelial Cells/drug effects/metabolism
MH  - Humans
MH  - Hyperhomocysteinemia/*drug therapy/metabolism
MH  - Inflammation/*drug therapy/metabolism
MH  - Iridoid Glucosides/*pharmacology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/metabolism
MH  - Oxidative Stress/*drug effects
MH  - Reactive Oxygen Species/metabolism
MH  - Signal Transduction/drug effects
MH  - Sirtuin 1/metabolism
MH  - Up-Regulation/drug effects
PMC - PMC6307770
OTO - NOTNLM
OT  - LOX-1
OT  - Picroside II
OT  - SIRT1
OT  - atherosclerosis
OT  - hyperhomocysteinemia
OT  - oxidative stress
EDAT- 2018/11/06 06:00
MHDA- 2020/04/16 06:00
PMCR- 2019/01/01
CRDT- 2018/11/06 06:00
PHST- 2018/05/27 00:00 [received]
PHST- 2018/09/03 00:00 [accepted]
PHST- 2018/11/06 06:00 [pubmed]
PHST- 2020/04/16 06:00 [medline]
PHST- 2018/11/06 06:00 [entrez]
PHST- 2019/01/01 00:00 [pmc-release]
AID - JCMM13949 [pii]
AID - 10.1111/jcmm.13949 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2019 Jan;23(1):464-475. doi: 10.1111/jcmm.13949. Epub 2018 Nov 5.